3 People Have Gotten Cancer-Detecting Implants in Their Brains

Coherence Neuro says it has temporarily implanted a cancer-detecting brain device in three people undergoing surgery to remove brain tumors, an early safety test for technology the company hopes could one day help treat glioblastoma.

WIRED reported on June 23, 2026, that the procedures took place at Royal Melbourne Hospital during tumor-removal surgery. The implant was left in place for about 30 minutes and then removed, making the work a temporary intraoperative test rather than a permanent implant study.

The company says the goal was to check short-term safety before moving toward longer-term implantation in patients with brain cancer. Coherence is initially aiming at glioblastoma, an aggressive form of brain cancer that can be difficult to monitor and treat after surgery.

What the implant is meant to do

According to WIRED, the device is a coin-sized brain-computer interface designed to detect electrical signals associated with tumors and deliver mild electrical stimulation. The broader concept rests on the idea that brain tumors may have distinctive electrical properties that can be sensed and, potentially, acted on.

That makes the implant different from a conventional cancer treatment device. The first reported human use was meant to test feasibility and safety in the operating room, not to prove that the device can treat cancer on its own.

The patients consented before surgery, WIRED reported. The temporary placement happened during the tumor-removal procedure, which allowed surgeons to test the device without leaving it implanted long term.

Why glioblastoma matters

Glioblastoma is one of the most aggressive brain cancers, with a high risk of recurrence. Doctors often rely on scans and follow-up visits to track whether the disease is returning or changing after surgery.

A device that could sense tumor-related electrical activity between MRI scans could, in theory, offer a more continuous view of what is happening inside the brain. That is the medical promise Coherence is exploring, but the company still has to show that the approach is safe, durable and useful.

The reported first-in-human testing also underscores how early this work remains. A brief surgical test can show whether a device can be used in people, but it does not answer the bigger questions about effectiveness, long-term implantation or clinical benefit.

Who is involved

WIRED said Coherence has ties to Neuralink. It also identified Matthew MacDougall as an adviser and investor in the company.

Rory Murphy is slated to be involved in future trials of the device, according to the report. Those details suggest the project is drawing on people with experience in brain-implant development, even as it remains in the early clinical phase.

The hospital setting is also important. Royal Melbourne Hospital was the site of the temporary implant procedures, placing the work inside a surgical context rather than a standalone device trial.

What comes next

Coherence says it plans to begin a glioblastoma trial next year with the device permanently implanted. WIRED reported that the planned next phase would move beyond the short-term temporary test and into a longer-term study.

The exact timing, size and oversight details of that trial were not public in the reporting available for this article. It is also not yet clear how many patients may be involved in the next phase.

For now, the key milestone is simply that the company says it has crossed into first-in-human testing. The result is an early proof-of-concept step, not evidence that the device works as a cancer treatment.

The next questions are whether Coherence or Royal Melbourne Hospital will publish more details about the procedure, whether any safety data emerge from the three-patient test, and how the planned glioblastoma study will be reviewed and run.